December 31, 2019

(Unaudited)

As previously

Adjustment

As Restated

reported

Statement of Operations

Amortization and depreciation

$

           49,234

 $

           (38,356)

 $

          10,878

Total Operating Expense

         320,358

           (38,356)

        282,002

Income/(Loss) from continuing operations before income taxes

         (13,758)

            38,356

          24,598

Net Income/(Loss)

         (37,184)

            38,356

            1,172

Net Income/(Loss) attributable to common stockholders

$

         (47,528)

 $

            38,356

 $

           (9,172)

Income/(Loss) from continuing operations

$

(0.00)

$

0.00

$

0.00

Income/(Loss) per common share - basic and diluted

$

(0.00)

$

0.00

$

(0.00)

December 31, 2019

(Unaudited)

As previously

Adjustment

As Restated

reported

Statement of Changes in Stockholders' Equity

Additional Paid in Capital

$

    15,641,402

 $

         (600,000)

 $

   15,041,402

Accumulated Deficit

  (16,258,294)

            38,356

  (16,219,938)

Total Stockholders' Deficit

       (614,565)

         (561,644)

    (1,176,209)

Total Liabilities and Stockholders' Deficit

$

         893,899

 $

         (561,644)

 $

        332,255

December 31, 2019

(Unaudited)

As previously

Adjustment

As Restated

reported

Statement of Cash Flow

Net Income/(Loss)

$

         (37,184)

 $

            38,356

 $

            1,172

Amortization of ReadyMed software platform

           38,356

           (38,356)

                    -

Supplemental disclosures of non-cash investing and financing activities:

Common stock issued for ReadyMed platform

$

         600,000

 $

         (600,000)

 $

                    -